
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is set to disrupt the healthcare industry with its innovative blood test for early cancer detection, and the upcoming ASCO data drop and ongoing FDA PMA review will likely solidify its position in the market. GRAIL has strong growth potential, as evidenced by its Q1 beat with 56,000 Galleri tests and 50% revenue growth year-over-year. There are risks, such as potential FDA approval delays or limitations on reimbursement, but GRAIL has a solid financial position with $823M in cash and is taking steps to expand its institutional adoption through seamless EMR integration and a growing sales force.
Bears say
GRAIL is facing challenges with its ASP compression, leading to speculation that its near-term revenue may be limited. Additionally, the company's focus on price elasticity and discounting programs, while possibly increasing awareness, may hurt its bottom line. Furthermore, materiality in ESG performance may vary across sectors, making it difficult to fully evaluate the company's performance.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares